HOME >> MEDICINE >> NEWS
Is complementary medicine cost effective?

More doubts are cast over the cost effectiveness of complementary medicine in this week's BMJ.

The cost-effectiveness of using complementary treatments in the United Kingdom has been the subject of much speculation and controversy.

For instance, a report commissioned by the Prince of Wales last week said that complementary therapies should be given a greater role in the NHS, while others believe that more studies are needed before they are made widely available.

As an example of how poor the evidence is, researchers carried out a systematic review of cost effectiveness analyses of complementary treatments. They found only five studies done in the UK before April 2005, one of acupuncture for headache and four of spinal manipulation for back pain.

They conclude that these treatments represent an additional cost to usual care with questionable clinical benefit.

In an accompanying editorial, two senior doctors and general practice researchers suggest that complementary medicine should be considered for inclusion in national clinical guidelines despite limited evidence of cost effectiveness.

They believe that the integration into the NHS of specific complementary therapies for chronic conditions would be beneficial to patients, but that each therapy needs to be considered on its merits, including cost-effectiveness.


'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-20-7383-6529
BMJ-British Medical Journal
13-Oct-2005


Page: 1

Related medicine news :

1. Should NICE evaluate complementary medicine?
2. Cancer patients hide their use of complementary and alternative treatments from their doctors
3. Pediatric use of complementary and alternative medicine
4. Surgery by satellite -- New possibilities at medicines cutting edge
5. New drug development facility helps move medicines to market
6. To get blood pressure under control, combination of medicines may be best
7. Italian doctors get their information on medicines from drug company sales reps
8. Nanomedicine opens the way for nerve cell regeneration
9. Conference to focus on transfer of knowledge from research to practice in emergency medicine
10. SNMs 54th Annual Meeting speakers address state of molecular imaging/nuclear medicine technologies
11. US Senate introduces bill to train more preventive medicine doctors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: complementary medicine cost effective

(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair ... following statement following the deadly earthquake in Nepal: , ... in the deaths of more than 1,000 people. ... Nepal, Bangladesh, India and other parts of South Asia. ... the people of Nepal and the families of the ...
(Date:4/25/2015)... April 25, 2015 By definition, a CIO’s ... for the enterprise relying on their judgement and expertise to ... But according to an article published in National Mortgage ... actually be doing a disservice to their responsibilities by focusing ... and t’s are crossed when it comes to company policy ...
(Date:4/25/2015)... April 25, 2015 Parker and Sons projects ... cooling, has spiked in Arizona alongside the growing economy. As ... forty employees for April to help account for the rising ... employees in April is something we are enthusiastic about. It ... Paul Kelly, president at Parker and Sons. , Indeed, Parker ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI Day ... in the nation! This year, on May 5th, 2015, Secura ... take DI Day on the road by supporting the first ... RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants and ... change by stating, "The first Twin Cities DI Day was ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 As the ... and the unique sacrifices of these young men and ... Service members, Veterans and their Families” presents a special ... is designed to gain a better understanding of the ... and wellness. For those – civilian and military – ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2
(Date:4/24/2015)... DUBLIN , Apr. 24, 2015 /PRNewswire/ ... ) has announced the addition of the ... Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station) & ... Institute) - Global Forecast to 2020" ... global laboratory accessories market is expected to ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. (NYSE: ... and increased its five-year revolving credit facility to $120 ... accordion feature that will allow the company to increase ... $30.0 million, subject to securing additional commitments from existing ... the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
Cached News: